This unique and in-depth symposium will provide an overview of the interplay between preclinical development, clinical, regulatory and Chemistry Manufacturing and Controls (CMC) in supporting the progression of novel therapeutics from clinical candidate nomination through market authorization. The discussion will focus on the design of an IND enabling and clinical development program to achieve the desired target product profile and product label.
Ian Hardy, Vice president of CMC for Deerfield Discovery and Development at Deerfield Management
Elizabeth Garner, MD, Chief Medical Officer of ObsEva
Brought to you by Cure by Deerfield
The Cure at 345 Park Avenue South, leading life science, digital health, and tech-enabled companies from across the world come together to uncover cutting-edge solutions for those in need. We provide laboratories, engineering and computing space, and other amenities and supportive services to help today’s thought leaders build a better tomorrow.